Previous Close | 1.0150 |
Open | 1.0000 |
Bid | 0.7056 x 200 |
Ask | 1.2100 x 200 |
Day's Range | 0.9502 - 1.0167 |
52 Week Range | 0.9400 - 9.3750 |
Volume | |
Avg. Volume | 1,138,042 |
Market Cap | 543,194 |
Beta (5Y Monthly) | 1.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -26.9500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that on October 19, 2023, NASDAQ notified us that it ha
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023TAIZHOU, China, Oct. 04, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("T
China SXT Pharmaceuticals ( NASDAQ:SXTC ) Full Year 2023 Results Key Financial Results Net loss: US$5.93m (loss widened...